Literature DB >> 19748580

Regulatory oversight of clinical trials in Africa: progress over the past 5 years.

Diadié Maïga1, Bartholomew Dicky Akanmori, Liliana Chocarro.   

Abstract

Randomized controlled clinical trials represent the best way to establish the therapeutic or preventive value of medicines. This decade has seen a strong shift in the location of clinical trials from industrialized countries to developing countries, including many in Africa. However, without independent strong regulatory and ethical oversight of clinical trials the safety of research subjects, and scientific integrity of clinical data cannot be verified. This article draws up a portrait of clinical trials regulation in Africa in support of development of priority medicines, highlights challenges and presents the progress made by countries under WHO guidance over the past 5 years.

Mesh:

Substances:

Year:  2009        PMID: 19748580     DOI: 10.1016/j.vaccine.2009.08.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Vaccine development and trials in low and lower-middle income countries: Key issues, advances and future opportunities.

Authors:  Amy Grenham; Tonya Villafana
Journal:  Hum Vaccin Immunother       Date:  2017-09-02       Impact factor: 3.452

2.  Operationalizing International Regulatory Standards in a Limited-Resource Setting During an Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Experience.

Authors:  Abdul Karim Kabineh; Wendy Carr; Mahnaz Motevalli; Jennifer Legardy-Williams; Willietta Vincent; Barbara E Mahon; Mohamed Samai
Journal:  J Infect Dis       Date:  2018-05-18       Impact factor: 5.226

3.  Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon.

Authors:  Sonali Kochhar
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

4.  Stakeholders' engagement with Ebola therapy research in resource limited settings.

Authors:  Morenike Oluwatoyin Folayan; Brandon Brown; Bridget Haire; Aminu Yakubu; Kristin Peterson; Jemee Tegli
Journal:  BMC Infect Dis       Date:  2015-06-26       Impact factor: 3.090

5.  Open-source mobile digital platform for clinical trial data collection in low-resource settings.

Authors:  Joris van Dam; Kevin Omondi Onyango; Brian Midamba; Nele Groosman; Norman Hooper; Jonathan Spector; Goonaseelan Colin Pillai; Bernhards Ogutu
Journal:  BMJ Innov       Date:  2017-01-06

6.  Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study.

Authors:  Jesse Gitaka; Caroline Ogwang; Moses Ngari; Pauline Akoo; Ally Olotu; Christine Kerubo; Greg Fegan; Patricia Njuguna; Godfrey Nyakaya; Tuda Otieno; Gabriel Mwambingu; Ken Awuondo; Brett Lowe; Roma Chilengi; James A Berkley
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

7.  Medicines Regulation in Africa: Current State and Opportunities.

Authors:  Margareth Ndomondo-Sigonda; Jacqueline Miot; Shan Naidoo; Alexander Dodoo; Eliangiringa Kaale
Journal:  Pharmaceut Med       Date:  2017-11-03

8.  Strengthening medical product regulation in low- and middle-income countries.

Authors:  Charles Preston; Mary Lou Valdez; Katherine Bond
Journal:  PLoS Med       Date:  2012-10-23       Impact factor: 11.069

9.  Ethical considerations in the conduct of research on therapies for the prevention and treatment of Ebola virus disease in developing countries.

Authors:  Morenike Oluwatoyin Folayan; Bridget Gabrielle Haire
Journal:  Pan Afr Med J       Date:  2015-10-10

10.  Ethics, emergencies and Ebola clinical trials: the role of governments and communities in offshored research.

Authors:  Morenike Oluwatoyin Folayan; Kristin Peterson; Frances Kombe
Journal:  Pan Afr Med J       Date:  2015-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.